<DOC>
	<DOCNO>NCT00004398</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate efficacy tin mesoporphyrin patient acute porphyria attack also treat standard course heme arginate . II . Evaluate safety tolerability tin mesoporphyrin administer patient .</brief_summary>
	<brief_title>Phase I Study Heme Arginate With Without Tin Mesoporphyrin Patients With Acute Attacks Porphyria</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , unblinded , multicenter study . Patients randomize receive heme arginate alone heme arginate tin mesoporphyrin . Patients receive single intravenous dose tin mesoporphyrin immediately first dose heme arginate . Heme arginate administer daily 4 day . Patients follow 3 6 day treatment .</detailed_description>
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Erythropoietic</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Documented acute intermittent porphyria , variegate porphyria , hereditary coproporphyria No chronic subacute symptom ( present longer 2 week ) Prior/Concurrent Therapy At least 3 week since prior treatment heme arginate tin mesoporphyrin Patient Characteristics Renal : Urinary porphobilinogen least 40 mg/24 hr Other : Not pregnant Fertile female patient must use effective contraception 6 month study No evidence symptom due another acute illness No acute hemorrhagic disorder : Gastrointestinal bleed Intracerebral hemorrhage No known sensitivity heme preparation tin mesoporphyrin No medical condition might increase risk patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>porphyria</keyword>
	<keyword>rare disease</keyword>
</DOC>